“This is a stepping stone vaccine towards a more normal world but it will not be a gamechanger for Pfizer’s bottom line. This is a first-generation vaccine that can help policymakers swing our lives back towards normal but it should be overtaken by more effective and durable second and third-generation vaccines in 2021.
“We anticipate initial market uptake should there be no safety issues. However, the idea of this being the final silver bullet for Covid may be mistaken. Durability, or how long immunity lasts in vaccine recipients, is a concern with mRNA-based vaccines like Pfizer’s, so we need to be very cautious of the 90% effectiveness rate we’re hearing about. There is also a question mark around whether Pfizer’s vaccine will be as effective amongst the elderly population.”